GENETIC TECHNOLOGIES LIMITED — AGM Information 2013

Nov 28, 2013

==> picture [595 x 72] intentionally omitted <==

==> picture [595 x 72] intentionally omitted <==

ASX ANNOUNCEMENT 29 November 2013

2013 Annual General Meeting

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached slide show presentation which will be delivered by its Acting Chief Executive Officer, Mr. Tom Howitt, at the Company’s 2013 Annual General Meeting to be held at approximately 10.40 am this morning in the “Treetops” Room at Melbourne Museum, 11 Nicholson Street, Carlton, Victoria, Australia.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr. Malcolm R. Brandon Chairman Genetic Technologies Limited (ABN 17 009 212 328) Telephone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Genetic Technologies Limited Tom Howitt ‐ Acting CEO Address

Annual General Meeting Friday, 29 November 2013

This presentation may contain forward‐looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward‐looking statements. By their nature, forward‐looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no

• Major focus on the expansion of US operations

• Significant and continuing growth in BREVAGen sample numbers received in each quarter, with 914 samples received during the September 2013 quarter

• Increase in US sales force from 10 to 15

• GTG lab now accredited to offer BREVAGen in all 50 US States

• • Number of covered lives increased to beyond 100 million

• KOL / Speaker program expanded to increase awareness

• Studies to broaden the existing product offering and expand

BREVAGen Quarterly Growth Launch to end of September 2013

1000

914

900

800

700

599

600

500

403

400

368

300

178 142

200

New Prescribers per Month Twelve months to October 2013

==> picture [627 x 299] intentionally omitted <==

----- Start of picture text -----

25
23
22
19 19 19
20
18
17
15
15
13 13
11
10
10
5
0
----- End of picture text -----

SVP Sales/Marketing

Western Dir of Sales

Eastern Dir of Sales

7 RBMs:

8 RBMs:

• ‐

• Seattle New England

• ‐

• Dallas Northeast

Director of Marketing

Office Manager

Accessioning Technician

• ‐

• Houston Ohio/Michigan

• Chicago

• DC/MD/VA

• ‐

• Southern California Florida

• ‐

• Missouri/Kansas New Jersey

• ‐ ‐ Northern NYC ‐

• California/Nevada KY/TN/IN

‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐

• Update current map….

• National/Regional/Local Press and Public Relations =

• http://www.youtube.com/watch?v VcyYFzeTFts

• October: “Accent Health” broadcast network =

• http://www.youtube.com/watch?v w_nrvmP7gZg

• Recent KOL/Speaker “Ambassador” Summit

• Professional Conferences

• Patient Advocacy

• Rick Frieder, MD, Consulting Chief Medical Officer; Pat McNamara, Medical speaker consultant and trainer; Courtney Tate, MBA, CGC, Phenogen Sciences, Director of Marketing

• 19 (of 23) Phenogen National Speakers attended

• Unified scientific and clinical message, enhanced presentation and speaking skills

• Demonstrating to MDs in the field the clinical value and simplicity of BREVAGen testing…fielding the tough questions from MDs and healthcare providers…conveying personal case studies and medical management wins…

• ACOG District 7 Regional Meeting

• Breast Cancer Challenge Conference

• Multidisciplinary Breast Care Conference

• Boca Raton Women’s Health Symposium

• ACOG Districts 5, 6, 8, and 9 Regional Meeting

• North American Menopause Society

• Mid‐Atlantic Women’s Care

• TMW: Take The Lead In Breast Cancer Care

• San Antonio Breast Cancer Symposium

= http://www.youtube.com/watch?v w_nrvmP7gZg

“BREVAGen saved my life”

BREVAGen 1.0: 7‐SNP assay, Caucasian‐only

• Indication is limiting, Caucasian population in the US = 62% only

• Recent advances in genetics need to be included

Within next 6 months: develop/launch BREVAGen 2.0

• Collaborators have been identified and relationships established

• Scientific evaluation and protocols have been designed

• Project plan with detailed timing and costings being finalised

• Initial case control study now underway

• Regulatory approval process and test validation being evaluated

• From 1 January 2013: ‘Miscellaneous’ CPT code vs. code stack

• Denials and follow‐on appeals have increased, but with strong PPO contracting and increased list price, average reimbursement for closed cases has increased overall

• Recent meeting held with primary payers seeking input for definition of clinical utility and supporting study design and output

• Priority: Further studies to generate additional peer‐reviewed data to strengthen ‘clinical utility’ evidence for payer

• Seven new licenses granted, taking the total to more than 77

• More than $73 million generated from licensing to date

• US assertion program continues in earnest, with 10 cases of infringement underway, including three against Big Pharma

• New assertion cases focussing of “762” mapping patent to extend the life of the licensing program

• European targets being independently pursued by GTG

• Third re‐exam of “179” patent successfully defended

• Challenges ahead: including further IP challenges and changes

• Australian sales continue to exceed budget

• Maintains technical capability in laboratory

• Spreads overhead expenses across broader operating base

• Growth opportunities exist from new tests and markets

ImmunAid

• Second round fundraising at $5.00 per share has commenced

• GTG retains 4.5 million shares and is 40+% major shareholder

• Further trials of ImmunAid technology being planned

Gtech International

• Acquisition of Simavita to be completed by Christmas

• $10 million now raised at issue price of $0.41 per share

• GTG retains 1.3 million shares

• Maintain focus on expansion of US operations

• Increase US sales force to cover all major US sales territories

• Complete and launch “second generation” BREVAGen test to improve performance and drive market acceptance in the US

• Broaden available ethnicities to expand available markets

• Work with payers to improve reimbursement outcomes

• Ensure adequate funding is available to meet objectives

• Maximise value from licensing, heritage business and the commercialisation of non‐core assets, whilst reducing costs

Tom Howitt Acting CEO Genetic Technologies Limited Phone +61 3 8412 7000 Email info@gtglabs.com